Clinical Trial Goal
To find out:
- The highest dose of INCA035784 that's safe to give
- If INCA035784 is safe and works well to treat MPN that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have MPN that has relapsed or is refractory. Some examples include:
- Essential thrombocythemia
- Primary myelofibrosis
- Have not had a blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
INCA035784 is a bispecific antibody that targets CD3 and mutCALR in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- INCA035784 – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
The clinical trial doctors will check your health for about 2.5 years.
The Food and Drug Administration (FDA) has not yet approved INCA035784.
The Food and Drug Administration (FDA) has not yet approved INCA035784.
Contacts
Incyte Corporation Call Center (US), 1.855.463.3463, medinfo@incyte.com
Incyte Corporation Call Center (ex-US), +800 00027423, eumedinfo@incyte.com
Locations
Sponsors
lead: Incyte Corporation
